Short Interest in Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Grows By 30.3%

Key Points

• Spectral Diagnostics Inc. experienced a significant increase in short interest of 30.3% in August, reaching 84,200 shares by the end of the month.
• The company's stock is currently trading at $1.07, with a 52-week range between $0.32 and $1.31.
• Spectral Diagnostics focuses on developing products for the treatment of septic shock, including its Endotoxin Activity Assay and Polymyxin B Hemoperfusion device.

Spectral Diagnostics Inc. (OTCMKTS:EDTXF - Get Free Report) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 84,200 shares, an increase of 30.3% from the August 15th total of 64,600 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily volume of 67,200 shares, the days-to-cover ratio is presently 1.3 days. Based on an average daily volume of 67,200 shares, the days-to-cover ratio is presently 1.3 days. Currently, 0.0% of the company's stock are short sold.

Spectral Diagnostics Trading Down 0.3%

EDTXF traded down $0.00 during trading hours on Friday, hitting $1.08. The company's stock had a trading volume of 200 shares, compared to its average volume of 30,193. Spectral Diagnostics has a 12 month low of $0.32 and a 12 month high of $1.31. The business's 50-day moving average price is $0.85 and its 200-day moving average price is $0.67. The stock has a market cap of $311.56 million, a price-to-earnings ratio of -15.46 and a beta of 0.27.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.